olesoxime

12/01/2015 - "The observed alleviation of behavioural and neuropathological phenotypes encourages further investigations on the use of olesoxime as a therapeutic for Huntington's disease."
10/01/2019 - "In our earlier preclinical studies, we demonstrated that administration of olesoxime in mouse and rat models of Huntington disease improved psychiatric and molecular phenotypes. "
01/01/2016 - "In a long-term treatment study in BACHD rats, the latest rat model of Huntington's disease, olesoxime revealed a positive influence on mitochondrial function and improved specific behavioral and neuropathological phenotypes. "
12/01/2015 - "Here, we investigated the therapeutic potential of olesoxime, a mitochondria-targeting, neuroprotective compound, in the BACHD rat model of Huntington's disease. "
08/01/2014 - "Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime."

01/01/2017 - "Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial."
12/01/2020 - "Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial."
10/01/2019 - "Numerous preclinical studies have successfully proved olesoxime's neuroprotective properties in cell and animal models of clinical conditions such as amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, peripheral neuropathy and spinal muscular atrophy. "
01/28/2010 - "Olesoxime (TRO19622) is a novel mitochondrial-targeted neuroprotective compound undergoing a pivotal clinical efficacy study in Amyotrophic Lateral Sclerosis (ALS) and also in development for Spinal Muscular Atrophy (SMA). "

10/01/2019 - "Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate."
08/01/2007 - "TRO19622 may have therapeutic potential for ALS and other motor neuron and neurodegenerative diseases."
01/01/2016 - "Olesoxime, a small molecule drug candidate, has recently attracted attention due to its significant beneficial effects in models of several neurodegenerative disorders including Huntington's disease. "
10/01/2019 - "Further research into the mode of action of olesoxime under pathological conditions, including its effect on neuronal calcium homeostasis, may strengthen the untapped potential of olesoxime or other similar compounds as a therapeutic for neurodegenerative diseases."
10/01/2019 - "Over the last years, the experimental compound olesoxime, a mitochondria-targeting cholesterol derivative, has emerged as a promising drug candidate for neurodegenerative diseases. "

02/01/2012 - "We also provide proof of concept that olesoxime could be useful for the treatment of demyelinating diseases."
11/01/2013 - "Using Female Sprague-Dawley rats models of demyelination, we morphologically and functionally assessed the effect of TRO19622 on myelination in vivo. "
11/01/2013 - "TRO19622 promotes myelin repair in a rat model of demyelination."
02/01/2012 - "In mouse models of demyelination and remyelination, olesoxime favored the repair process, promoting myelin formation with consequent functional improvement. "
02/01/2012 - "Olesoxime accelerates myelination and promotes repair in models of demyelination."

01/01/2020 - "TRO19622 improves mitochondrial dysfunction but enhances Aβ levels in disease models of AD. "
08/01/2014 - "Thus, olesoxime may represent a novel pharmacological tool to treat mitochondrial dysfunction in HD."
01/01/2020 - "Olesoxime improves cerebral mitochondrial dysfunction and enhances Aβ levels in preclinical models of Alzheimer's disease."
01/01/2020 - "Rotenone-induced mitochondrial dysfunction perturbed the exocytotic release of FM1-43 and cell-permeable VDAC inhibitor (but not olesoxime or impermeable VDAC inhibitor) partially mitigated the rotenone-driven alterations in the FM1-43 unloading and mitochondrial superoxide production. "
01/01/2020 - "Olesoxime (TRO19622) has been tested in AD disease models characterized by improved amyloid precursor protein processing (AβPP) and mitochondrial dysfunction. "